Blocking IL1β pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis

Molecular Cancer Therapeutics

Volumn 14, Issue 6, 2015, Pages 1385-1394

  Voloshin, Tali ^a   Alishekevitz, Dror ^a   Kaneti, Limor ^a   Miller, Valeria ^a   Isakov, Elina ^a   Kaplanov, Irena ^b   Voronov, Elena ^b   Fremder, Ella ^a   Benhar, Moran ^a   Machluf, Marcelle ^a   Apte, Ron N ^b   Shaked, Yuval ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; PACLITAXEL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CAPILLARY DENSITY; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MACROPHAGE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; METASTASIS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MACROPHAGES; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; RECEPTORS, INTERLEUKIN-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84942082818     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0969     Document Type: Article

References (31)

1. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-25.
2. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011;25:2465-79.
3. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013;19:57-64.
4. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013;38:729-41.
5. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, et al. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci U S A 2011;108:10662-7.
6. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
7. Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, Voloshin T, et al. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 2011;71:6986-96.
8. Voloshin T, Voest EE, Shaked Y. The host immunological response to cancer therapy: An emerging concept in tumor biology. Exp Cell Res 2013;319:1687-95.
9. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006;25:387-408.
10. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-12.
11. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanismof action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
12. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-86.
13. Adini A, Fainaru O, Udagawa T, Connor KM, Folkman J, D'Amato RJ. Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J Immunol Methods 2009;342:78-81.
14. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010;10:89-102.
15. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50.
16. O'Brien JM Jr., Wewers MD, Moore SA, Allen JN. Taxol and colchicine increase LPS-induced pro-IL-1 beta production, but do not increase IL-1 beta secretion. A role for microtubules in the regulation of IL-1 beta production. J Immunol 1995;154:4113-22.
17. Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, et al. The role of IL-1beta in the early tumor cell-induced angiogenic response. J Immunol 2013;190:3500-9.
18. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest 2005;115:2979-91.
19. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011;19:31-44.
20. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
21. Huang Q, Lan F, Wang X, Yu Y, Ouyang X, Zheng F, et al. IL-1betainduced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer 2014;13:18.
22. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003;100:2645-50.
23. Eberhardt W, Huwiler A, Beck KF, Walpen S, Pfeilschifter J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NFkappa B and activating protein-1 and involves activation of the mitogenactivated protein kinase pathways. J Immunol 2000;165:5788-97.
24. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 2011;186:3462-71.
25. De Nardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
26. Shurin MR. Dual role of immunomodulation by anticancer chemotherapy. Nat Med 2013;19:20-2.
27. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011;11:135-41.
28. Alishekevitz D, Bril R, Loven D, Miller V, Voloshin T, Gingis-Velistki S, et al. Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing. Mol Cancer Ther 2014;13:202-13.
29. Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 2010;29:317-29.
30. Cao Y, Jiao Y, Wang L, Huang Y, Postlethwaite A, Stuart J, et al. Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts-from the point of view of mouse genomics. Int Immunopharmacol 2012;13:28-36.
31. Molto A, Olive A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010;77:102-7.